Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy

Am J Hematol. 2021 Nov 1;96(11):E443-E446. doi: 10.1002/ajh.26348. Epub 2021 Sep 22.

Authors

Sandra Lockmer^{1

2}, Katarina Uttervall^{1

2}, Muhammad Kashif¹, Carina Svärd², Katarina Malmsten², Evellyn Fletcher-Torres², Evren Alici^{1

2}, Johan Lund^{1

2}, Hareth Nahi^{1

2}

Affiliations

¹ Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
² Hematology Center, Karolinska University Hospital, Stockholm, Sweden.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Vaccines / administration & dosage*
Humans
Immunotherapy / methods*
Melphalan / administration & dosage*
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology*

Substances

COVID-19 Vaccines
Melphalan